

RESEARCH PAPER



Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNA

Andrea Bistrović^a, Luka Krstulović^b, Ivana Stolić^b, Domagoj Drenjančević^{c,d}, Jasminka Talapko^d, Martin C. Taylor^e, John M. Kelly^e, Miroslav Bajić^b and Silvana Raić-Malić^a

^aDepartment of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Zagreb, Croatia; ^bDepartment of Chemistry and Biochemistry, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia; ^cDepartment of Transfusion Medicine, Osijek University Hospital, Osijek, Croatia; ^dDepartment of Microbiology and Parasitology, Faculty of Medicine, University of Osijek, Osijek, Croatia; ^eDepartment of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, UK

ABSTRACT


Amidinobenzimidazole derivatives connected to 1-aryl-substituted 1,2,3-triazole through phenoxymethylene linkers **7a–7e**, **8a–8e**, and **9a–9e** were designed and synthesised with the aim of evaluating their anti-bacterial and anti-trypanosomal activities and DNA/RNA binding affinity. Results from anti-bacterial evaluations of antibiotic-resistant pathogenic bacteria revealed that both *o*-chlorophenyl-1,2,3-triazole and *N*-isopropylamidine moieties in **8c** led to strong inhibitory activity against resistant Gram-positive bacteria, particularly the MRSA strain. Furthermore, the non-substituted amidine and phenyl ring in **7a** induced a marked anti-bacterial effect, with potency against ESBL-producing Gram-negative *E. coli* better than those of the antibiotics ceftazidime and ciprofloxacin. UV–Vis and CD spectroscopy, as well as thermal denaturation assays, indicated that compounds **7a** and **8c** showed also binding affinities towards ctDNA. Anti-trypanosomal evaluations showed that the *p*-methoxyphenyl-1,2,3-triazole moiety in **7b** and **9b** enhanced inhibitory activity against *T. brucei*, with **8b** being more potent than nifurtimox, and having minimal toxicity towards mammalian cells.

ARTICLE HISTORY

Received 25 January 2018
Revised 18 May 2018
Accepted 31 May 2018

KEYWORDS

Benzimidazole; 1,2,3-triazole; resistant bacteria; antiprotozoal activity; *Trypanosoma brucei*; MRSA






Introduction

The benzimidazole derivatives, which contain fused heterocyclic nuclei within their structures, are structural isosteres of purine bases. This allows them to interact with biopolymers and they, therefore, have diverse biological and clinical applications^{1–5}. Much research effort has been aimed at targeting DNA with benzimidazole ligands, with the goal of designing agents that have therapeutic applications^{5–9}. Although RNA is a well-established target of current antibiotics, designing new compounds that selectively recognise RNA has also been a difficult task, particularly when focused on the treatment of a variety of infections^{10–12}. The challenge is to produce drug-like molecules with high affinity for DNA/RNA, while maintaining sufficient sequence selectivity. While

there are many areas of therapy that might benefit from DNA-directed intervention, there is currently an urgent need for new antimicrobials with novel modes of action.

Antibiotic resistance is a global public threat because of its effect on health care with prolonged hospitalisations and increased mortality. The increasing prevalence of hospital and community-acquired infections caused by multidrug-resistant (MDR) bacterial pathogens is limiting the options for effective antibiotic therapy^{13,14}. Drug-resistant Gram-positive bacterial pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *enterococci* (VRE), have become a serious clinical problem that impinges on the treatment of various nosocomial and community-acquired infections^{15,16}. In addition, an increased incidence of MDR Gram-negative bacteria, such as

CONTACT Silvana Raić-Malić  sraic@fkit.hr  Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 20, HR-10000 Zagreb, Croatia

 Supplemental data for this article can be accessed [here](#).

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Representatives of benzimidazoles containing triazole moiety I–V as potential antibacterial agents.



Figure 2. Aromatic amidines and 1,4-diphenyl-1,2,3-triazole amidine VI as anti-HAT agents.

Pseudomonas aeruginosa, *Escherichia coli*, and *Klebsiella pneumoniae*, coupled with the lack of novel antibiotics, represents one of the biggest threats to the control of respiratory and other infections¹⁷. In order to overcome these emerging bacterial resistance problems, novel anti-bacterial drugs need to be developed. Accordingly, in recent years, numerous efforts have focused on discovering novel benzimidazole-based anti-bacterial agents^{18–24}. The importance of a protonable chemical moiety within anti-bacterial drugs has been investigated in different studies^{25,26}. These have revealed the significant uptake of amidine-containing DNA ligands into bacteria, and also into the nuclei of eukaryotic cells²⁷. In addition, the structural features of 1,2,3-triazole also enable it to mimic different functional groups, justifying its wide use as a bioisostere for the design of antimicrobial drug analogs^{28,29}. For example 1,4-disubstituted 1,2,3-triazoles are good Z-amide isosteres, because the C-4 atom can act as an electrophilic site; the CH bond (in the 5-position) acts as a hydrogen bond donor, and the lone pair of N-3 electrons acts as a hydrogen bond acceptor³⁰.

A wide range of pharmacological activities has been attributed to the unusual chemical features ofazole rings, such as benzimidazole and 1,2,3-triazole. These are able to interact in a non-covalent way with a range of targets, due to the presence of an electron-rich aromatic system and heteroatoms^{31,32}, and act as promising moieties for the design of novel scaffolds with anti-bacterial activity. Thus, among the series of [1,2,4-triazolyl]phenyl-substituted 4,6-difluorobenzimidazoles I³³, analogues with electronegative substituents emerged as promising antimicrobials, while 2-thiobenzimidazole with [(1,2,4-triazolyl)ethylthio]phenyl moiety II³⁴ exhibited anti-bacterial properties that were selective for *Helicobacter pylori* (Figure 1). Benzimidazole–1,2,3-triazole conjugates III with aromatic (*p*-chlorophenyl and *p*-fluorophenyl) 4-substituted triazoles exhibited selective anti-*Moraxella catarrhalis* activity³⁵. Furthermore,

triazole-bearing monobenzimidazoles IV and V inhibited growth of Gram-positive bacteria, including two MRSA strains, and displayed *E. coli* DNA topoisomerase I inhibition³⁶.

The increasingly important role of benzimidazole and triazole derivatives has been also demonstrated by their *in vivo* evaluations against Gram-positive^{37–42} and Gram-negative bacteria⁴³. Bis-benzimidazole compound (ridinilazole, SMT-19969)⁴⁴ recently entered phase III human clinical trials for the treatment of *Clostridium difficile*.

Besides anti-bacterial activity, benzimidazole containing compounds have shown good anti-protozoal potency^{45–49}. Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by two subspecies of *Trypanosoma brucei*. It has been estimated that over 50 million people are at risk of infection with HAT in more than 30 African countries, and there remains a clear need to develop new, safer, and more affordable agents to combat this fatal infection⁵⁰. The efficacy of diarylamidines, such as pentamidine⁵¹, berenyl⁵² and its orally active prodrug pafuramide⁵³ (Figure 2), in the treatment of protozoal diseases, especially trypanosomiasis, has been known for many years.

However, current drugs have problems, such as toxicity, poor efficacy, and increasing resistance by the parasites. Although the precise anti-protozoan mechanisms of action of aromatic diamidines have not been fully elucidated, there is considerable evidence that direct interaction with the pathogen genome is important for activity. Recently, a diamidine containing a 1,2,3-triazole ring as central core was synthesised, which displayed better anti-trypanosomal efficacy than melarsoprol, curing all infected mice⁵⁴. It was found that incorporation of different hydrophobic aromatic head groups linked to the rest of the molecule by an amidine moiety improved both anti-bacterial activity and affinity to DNA²⁷.




Figure 3. Design and synthesis of amidinobenzimidazoles connected to 1-aryl-substituted 1,2,3-triazole via phenoxyethylene unit.

In view of the wide applications of the benzimidazole and 1,2,3-triazole moieties in drug development, and encouraged by the activity profile of both scaffolds^{35,55}, we synthesised molecules that contained both units attached through a phenoxyethylene linker as the central core, thereby expanding the electronic environment of chemical space (Figure 3).

Targeted compounds were designed to contain a non-substituted amidine, *N*-isopropylamidino, and imidazolium moiety at the C-5 position of the benzimidazole core, as the hydrophilic end, and an aromatic unit at the N-1 position of the 1,2,3-triazole ring, as the hydrophobic end. It was anticipated that selected 5-amidinobenzimidazoles connected to 1-aryl-substituted 1,2,3-triazole would exhibit enhanced affinity for DNA/RNA compared to other aromatic amidines that we have recently studied^{56,57}. Therefore, interactions between 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** and DNA/RNA were assessed and their activities against Gram-positive, Gram-negative, and antibiotic-resistant, as well as their trypanocidal properties, were evaluated.

Materials and methods

General

All chemicals and solvents were purchased from Aldrich and Acros. Pre-coated Merck silica gel 60F-254 plates and Fluka (0.063–0.2 mm) silica gel using an appropriate solvent system were employed for thin layer chromatography (TLC) and column chromatography, respectively. Melting points were determined using Kofler micro hot-stage (Reichert, Vienna, Austria). ¹H and ¹³C NMR spectra were recorded on a Varian Gemini 300 and 600 spectrometers. All NMR spectra were recorded in DMSO-*d*₆ at 298 K. Mass spectra were recorded on an Agilent 6410 instrument with electrospray interface and triple quadrupole analyser. Microwave-assisted syntheses were carried out in a microwave oven (Milestone start S) at 80 °C and pressure of 1 bar. The ultrasound-assisted reactions were performed in a bath cleaner (Bandelin, Sonorex digital 10 P, Berlin, Germany) with frequency of 35 kHz and power of 1000 W.

Experimental procedures for the synthesis of compounds

Amidino-substituted *o*-phenylenediamines (**4–6**)⁵⁸, 4-(prop-2-yn-1-yloxy)benzaldehyde (**2**)⁵⁹, 4-(1,2,3-triazol-4-yl)methoxybenzaldehyde (**3b**)⁶⁰, 4-(1,2,3-triazol-4-yl)methoxybenzaldehydes (**3a**, **3d**), and 5-amidinobenzimidazoles (**7a**, **7d**, **8a**, **8d**, **9a**, and **9d**)⁵⁵ were prepared according to described procedures.

General procedure for the synthesis of compounds 3a–e

The reaction mixture of compound **2**, Cu(0) (0.8 eq), 1 M CuSO₄ (0.3 eq) and the corresponding azide (1.2 eq) was dissolved in 1 ml DMF and a mixture of *t*-BuOH: H₂O = 1: 1 (3 ml). Method A: The reaction mixture was stirred under microwave irradiation (300 W) at 80 °C during 1.5 h. Method B: The reaction mixture was placed in an ultrasonic bath cleaner (1000 W, 35 kHz) at 80 °C for 1.5 h. The solvent was removed under reduced pressure and purified by column chromatography with CH₂Cl₂.

4-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyleneoxy)benzaldehyde (**3b**)

Compound **3b** was prepared using the above mentioned procedure from **2** (200 mg, 1.15 mmol) and 1-azido-4-methoxybenzene (2.76 ml, 1.38 mmol) to obtain **3b** as white crystals (Method A: 149.3 mg, 42%; Method B: 271.2 mg, 76%; m.p. 127–130 °C) (m.p. lit.⁶⁰ = 126–127 °C). ¹H NMR (300 MHz, DMSO) δ 9.89 (1H, s, CHO), 8.87 (1H, s, H5'), 7.90 (2H, d, *J* = 8.8 Hz, Ph), 7.81 (2H, d, *J* = 9.1 Hz, Ph), 7.28 (2H, d, *J* = 8.7 Hz, Ph), 7.14 (2H, d, *J* = 9.1 Hz, Ph), 5.36 (2H, s, OCH₂), 3.83 (3H, s, OCH₃). ¹³C NMR (75 MHz, DMSO) δ 191.55, 162.99, 159.49, 143.08, 131.96, 130.03, 130.00, 123.25, 122.03, 115.35, 115.03, 61.47, 55.68.

4-((1-(2-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde (**3c**)

Compound **3c** was prepared using the above mentioned procedure from **2** (200 mg, 1.15 mmol) and 1-azido-2-chlorobenzene (2.76 ml, 1.38 mmol) to obtain **3c** as white solid (Method A: 194.2 mg, 53%; Method B: 231.67 mg, 64%; m.p. = 127–129 °C). ¹H NMR (600 MHz, DMSO) δ 9.90 (1H, s, CHO), 8.76 (1H, s, H5'), 7.91 (2H, d, *J* = 8.7 Hz, Ph), 7.79 (1H, dd, *J* = 8.0, 1.2 Hz, Ph), 7.73 (1H, dd, *J* = 7.8, 1.6 Hz, Ph), 7.65 (1H, td, *J* = 7.8, 1.6 Hz, Ph), 7.60 (1H, td, *J* = 7.6, 1.3 Hz, Ph), 7.30 (2H, d, *J* = 8.7 Hz, Ph), 5.40 (s, 2H, OCH₂). ¹³C NMR (151 MHz, DMSO) δ 191.84, 163.15, 142.48, 134.54, 132.14, 132.10, 130.84, 130.19, 128.81, 128.74, 128.63, 127.35, 115.54, 61.40.

4-((1-((Phenylthio)methyl)-1H-1,2,3-triazol-4-yl)methoxy)benzaldehyde (**3e**)

Compound **3e** was prepared using the above mentioned procedure from **2** (200 mg, 1.15 mmol), azidomethyl phenyl sulfide (0.19 ml, 1.38 mmol), Cu (0) (59.8 mg, 0.94 mmol), 1 M CuSO₄ (0.24 ml, 0.05 mmol) in DMF (1 ml), *t*-BuOH: H₂O = 1: 1 (4 ml) to obtain **3e** as yellow oil (Method A: 214.3 mg, 57%; Method B: 273.6 mg, 73%). ¹H NMR (300 MHz, DMSO) δ 9.88 (1H, s, CHO), 8.21 (1H, s, 1H, H5'), 7.87 (2H, d, *J* = 8.8 Hz, Ph), 7.43–7.26 (5H, m, Ph),

7.21 (2H, d, $J=8.7$ Hz, Ph), 5.96 (2H, s, 2H, CH₂), 5.26 (2H, s, CH₂). ¹³C NMR (75 MHz, DMSO) δ 191.58, 162.94, 142.57, 132.36, 131.92, 130.68, 129.98, 129.43, 127.90, 124.72, 115.36, 61.33, 51.87.

General procedure for the synthesis of compounds 7a–7e, 8a–8e, and 9a–9e

The reaction mixture of 4-triazolylbenzaldehyde derivatives (**3a–3e**), *o*-phenylenediamine (**4**, **5**, or **6**) and 40% NaHSO₃ was dissolved in 15 ml EtOH and stirred under reflux for 6–8 h. After completion of the reaction NaHSO₃ (aq) was filtered and the reaction mixture was evaporated to dryness. Water was added (5 ml) and the mixture was stirred overnight and filtered. The crude residue was dissolved in HCl saturated MeOH (8–10 ml) and stirred overnight. Addition of ether resulted in precipitation of products **7a–7e**, **8a–8e**, and **9a–9e**. Solid was collected by filtration, washed with anhydrous ether, and dried under vacuum.

2-(4-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (7b)

Compound **7b** was prepared using the above described method from **3b** (200 mg, 0.65 mmol) and **4** (87.39 mg, 0.58 mmol) to obtain **7b** as white powder (122.7 mg, 53%, m.p. = 195–197 °C). ¹H NMR (600 MHz, DMSO) δ 9.35 (2H, s, NH), 8.94 (2H, s, NH), 8.90 (1H, s, H5'), 8.26 (2H, d, $J=8.2$ Hz, Ph), 8.15 (1H, s, H4), 7.84–7.80 (3H, m, Ph; H7), 7.71 (1H, d, $J=8.0$ Hz, H6), 7.34 (2H, d, $J=8.7$ Hz, Ph), 7.15 (2H, d, $J=9.0$ Hz, Ph), 5.37 (2H, s, OCH₂), 3.84 (3H, s, OCH₃). ¹³C NMR (75 MHz, DMSO) δ 165.85, 160.58, 159.42, 153.78, 143.21, 140.84, 134.73, 129.97, 129.13, 123.14, 122.69, 121.93, 120.61, 115.55, 114.97, 61.34, 55.63. MS (ESI, m/z) 440.1 [M+H]⁺. Anal. calcd. for C₂₄H₂₁N₇O₂ × 2 HCl × 2.5 H₂O (Mr = 557.44): C 51.71, H 5.06, N 17.59; found: C 51.60, H 4.72, N 17.34%.

2-(4-((1-(2-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (7c)

Compound **7c** was prepared using the above described method from **3c** (200 mg, 0.64 mmol) and **4** (96.51 mg, 0.64 mmol) to obtain white powder **7c** (210.3 mg, 58%, m.p. = 176–177 °C). ¹H NMR (300 MHz, DMSO) δ 9.36 (2H, s, NH), 8.96 (2H, s, NH), 8.77 (1H, s, 1H, H5'), 8.28 (2H, d, $J=8.8$ Hz, Ph), 8.16 (1H, s, H4), 7.88–7.55 (6H, m, Ph; H5; H6), 7.36 (2H, d, $J=8.9$ Hz, Ph), 5.40 (2H, s, OCH₂). ¹³C NMR (151 MHz, DMSO) δ 165.62, 161.33, 152.72, 142.25, 134.41, 131.84, 131.26, 130.60, 129.84, 128.51, 127.23, 123.76, 123.22, 122.24, 115.90, 115.70, 114.82, 61.23. MS (ESI, m/z) 444.0 [M+H]⁺. Anal. calcd. for C₂₃H₁₈ClN₇O × 2 HCl × 3 H₂O (Mr = 570.86): C 48.39, H 4.59, N 17.17; found: C 48.11, H 4.47, N 17.38%.

2-(4-((1-(Phenylthio)methyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (7e)

Compound **7e** was prepared using the above described method from **3e** (200 mg, 0.64 mmol) and **4** (96.51 mg, 0.64 mmol) to obtain **7e** as white powder (324.8 mg, 90%, m.p. = 173–176 °C). ¹H NMR (300 MHz, DMSO) δ 9.46 (2H, s, NH), 9.08 (2H, s, NH), 8.34 (2H, d, $J=8.9$ Hz, Ph), 8.25 (1H, s, H5'), 8.20 (1H, d, $J=1.1$ Hz, H4), 7.89 (2H, t, $J=7.8$ Hz, Ph), 7.80 (1H, dd, $J=8.6$ Hz, H6), 7.45–7.29 (6H, m, H7; Ph), 5.99 (2H, s, CH₂), 5.30 (2H, s, CH₂). ¹³C NMR (75 MHz, DMSO) δ 165.70, 161.12, 153.11, 142.62, 139.17, 132.38, 131.84, 130.59, 129.59, 129.38, 127.82, 124.66, 123.55, 122.98, 115.72, 115.30, 61.27, 51.80. MS (ESI, m/z) 456.1 [M+H]⁺. Anal. calcd. for C₂₄H₂₁N₇OS × 2 HCl × 1.7 H₂O (Mr = 559.09): C 51.56, H 4.76, N 17.54; found: C 51.80, H 4.68, N 17.22%.

N-isopropyl-2-(4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (8b)

Compound **8b** was prepared using the above described method from **3b** (200 mg, 0.65 mmol) and **5** (115.2 mg, 0.65 mmol) to obtain **8b** as brown powder (225.8 mg, 58%, m.p. = 188–191 °C). ¹H NMR (300 MHz, DMSO) δ 9.66 (1H, d, $J=7.7$ Hz, NH), 9.51 (1H, s, NH), 9.08 (1H, s, NH), 8.92 (1H, s, H5'), 8.39 (2H, d, $J=8.7$ Hz, Ph), 8.08 (1H, s, H4), 7.88 (1H, d, $J=8.5$ Hz, H7), 7.83 (2H, d, $J=9.0$ Hz, Ph), 7.69 (1H, d, $J=7.6$ Hz, H6), 7.39 (2H, d, $J=8.8$ Hz, Ph), 7.15 (2H, d, $J=9.0$ Hz, Ph), 5.39 (2H, s, CH₂), 4.15–4.02 (1H, m, CH), 3.84 (3H, s, OCH₃), 1.32 (6H, d, $J=6.3$ Hz, CH₃CHCH₃). ¹³C NMR (151 MHz, DMSO) δ 162.18, 161.13, 159.50, 152.96, 143.20, 130.02, 129.64, 124.28, 124.21, 123.74, 123.30, 122.03, 115.77, 115.36, 115.05, 61.43, 55.71, 45.25, 21.38. MS (ESI, m/z) 482.1 [M+H]⁺. Anal. calcd. for C₂₇H₂₇N₇O₂ × 2 HCl × 2.6 H₂O (Mr = 601.32): C 53.93, H 5.73, N 16.30; found: C 53.62, H 5.71, N 16.39%.

N-isopropyl-2-(4-((1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (8c)

Compound **8c** was prepared using the above described method from **3c** (200 mg, 0.64 mmol) and **5** (101.0 mg, 0.57 mmol) to obtain **8c** as white powder (105.5 mg, 28%, m.p. = 210–213 °C). ¹H NMR (300 MHz, DMSO) δ 9.58 (1H, d, $J=8.2$ Hz, NH), 9.43 (1H, s, NH), 8.99 (1H, s, NH), 8.78 (1H, s, H5'), 8.30 (2H, d, $J=8.6$ Hz, Ph), 8.04 (1H, s, H4), 7.87–7.57 (6H, m, H7; H6; Ph), 7.37 (2H, d, $J=8.4$ Hz, Ph), 5.40 (2H, s, OCH₂), 4.13–4.00 (1H, m, CH), 1.31 (6H, d, $J=6.1$ Hz, CH₃CHCH₃). ¹³C NMR (151 MHz, DMSO) δ 162.41, 160.38, 153.72, 142.46, 134.42, 131.84, 130.61, 128.93, 128.57, 128.55, 128.47, 127.09, 123.10, 127.09, 122.58, 120.24, 116.13, 115.53, 61.14, 45.06, 21.31. MS (ESI, m/z) 486.1 [M+H]⁺. Anal. calcd. for C₂₆H₂₄ClN₇O × 2 HCl × 2.3 H₂O (Mr = 600.33): C 52.02, H 5.14, N 16.33; found: C 52.22, H 5.03, N 16.59%.

N-isopropyl-2-(4-((1-(phenylthiomethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole-5-carboximidamide dihydrochloride (8e)

Compound **8e** was prepared using the above described method from **3e** (200 mg, 0.61 mmol) and **5** (108.9 mg, 0.61 mmol) to obtain **8e** as yellow powder (73.1 mg, 21%, m.p. = 152–154 °C). ¹H NMR (600 MHz, DMSO) δ 9.66 (1H, d, $J=7.5$ Hz, NH), 9.51 (1H, s, NH), 9.09 (1H, s, NH), 8.39 (2H, d, $J=7.9$ Hz, Ph), 8.25 (1H, s, H5'), 8.08 (1H, s, H4), 7.87 (1H, d, $J=8.3$ Hz, H7), 7.68 (1H, d, $J=8.5$ Hz, H6), 7.40 (2H, d, $J=7.5$ Hz, Ph), 7.36–7.15 (5H, m, Ph), 5.98 (2H, s, CH₂), 5.29 (2H, s, CH₂), 4.24–3.99 (1H, m, CH), 1.31 (6H, d, $J=6.4$ Hz, CH₃CHCH₃). ¹³C NMR (75 MHz, DMSO) δ 162.93, 160.52, 154.42, 145.37, 143.19, 132.82, 130.98, 129.76, 129.09, 128.18, 124.99, 123.19, 122.71, 122.05, 115.86, 61.55, 52.18, 45.44, 21.75. MS (ESI, m/z) 498.1 [M+H]⁺. Anal. calcd. for C₂₇H₂₇N₇OS × 2 HCl × 0.3 H₂O (Mr = 575.95): C 56.31, H 5.18, N 17.02; found: C 56.33, H 5.37, N 17.28%.

5-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole dihydrochloride (9b)

Compound **9b** was prepared using the above described method from **3b** (200 mg, 0.65 mmol) and **6** (114.9 mg, 0.65 mmol) to obtain **9b** as yellow powder (279.1 mg, 70%, m.p. = 197–199 °C). ¹H NMR (300 MHz, DMSO) δ 10.68 (2H, s, NH), 8.91 (1H, s, H5'),

8.37 (1H, s, H4), 8.32 (2H, d, $J=8.3$ Hz, Ph), 7.88 (1H, d, $J=4.3$ Hz, H7), 7.82 (2H, d, $J=8.5$ Hz, Ph), 7.35 (2H, d, $J=8.1$ Hz, Ph), 7.28 (1H, d, $J=8.3$ Hz, H6), 7.15 (2H, d, $J=8.1$ Hz, Ph), 5.37 (2H, s, OCH₂), 4.03 (4H, s, CH₂CH₂), 3.83 (3H, s, OCH₃). ¹³C NMR (151 MHz, DMSO) δ 165.49, 160.68, 159.51, 154.27, 143.30, 143.09, 136.43, 131.97 (C4), 130.01 (Ph-q), 129.27 (Ph), 123.21 (C6), 123.00 (C5'), 122.04 (Ph), 120.62 (C5), 116.05, 115.63, 115.37, 115.06, 61.38, 55.72, 44.44. MS (ESI, m/z) 466.1 [M+H]⁺. Anal. calcd. for C₂₆H₂₃N₇O₂ × 2 HCl × 0.9 H₂O (Mr = 554.65): C 56.30, H 4.87, N 17.68; found: C 56.04, H 4.72, N 17.97%.

5-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-((1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole dihydrochloride (9c)

Compound **9c** was prepared using the above described method from **3c** (200 mg, 0.64 mmol) and **6** (112.9 mg, 0.64 mmol) to obtain **9c** as red powder (115.3 mg, 30%, m.p. = 194–196 °C). ¹H NMR (600 MHz, DMSO) δ 10.82 (2H, s, NH), 8.81 (1H, s, H5'), 8.45 (1H, s, H4), 8.40 (2H, d, $J=8.6$ Hz, Ph), 7.98 (1H, d, $J=8.5$ Hz, H7), 7.93 (1H, d, $J=8.3$ Hz, H6), 7.81 (1H, dd, $J=8.0, 1.2$ Hz, Ph), 7.75 (1H, dd, $J=7.8, 1.6$ Hz, Ph), 7.67 (1H, td, $J=7.8, 1.6$ Hz, Ph), 7.62 (1H, td, $J=7.7, 1.3$ Hz, Ph), 7.40 (2H, d, $J=8.9$ Hz, Ph), 5.43 (2H, s, OCH₂), 4.04 (4H, s, CH₂CH₂). ¹³C NMR (75 MHz, DMSO) 165.20, 161.07, 153.69, 142.40, 138.84, 136.92, 134.44, 131.90, 130.66, 130.15, 129.62, 128.63, 128.52, 127.21, 123.57, 119.46, 116.66, 116.38, 115.69, 61.24, 44.42. MS (ESI, m/z) 470.1 [M+H]⁺. Anal. calcd. for C₂₅H₂₀ClN₇O × 2 HCl × 1.9 H₂O (Mr = 577.08): C 52.03, H 4.51, N 16.99; found: C 52.31, H 4.66, N 16.63%.

5-(4,5-Dihydro-1H-imidazol-2-yl)-2-(4-((1-(phenylthiomethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benz[d]imidazole dihydrochloride (9e)

Compound **9e** was prepared using the above described method from **3e** (200 mg, 0.61 mmol) and **6** (108.9 mg, 0.61 mmol) to obtain **9e** as brown powder (149.4 mg, 41%, m.p. = 162–164 °C). ¹H NMR (300 MHz, DMSO) δ 10.57 (2H, s, NH), 8.34–8.18 (4H, m, H5'; H4; Ph), 7.85 (2H, s, H7; H6), 7.44–7.21 (7H, m, Ph), 5.97 (2H, s, CH₂), 5.26 (2H, s, CH₂), 4.03 (4H, s, CH₂CH₂). ¹³C NMR (151 MHz, DMSO) δ 165.13, 162.84, 160.80, 153.75, 142.60, 132.38, 131.79, 130.48, 129.86, 129.40, 129.32, 127.72, 124.63, 116.37, 115.52, 115.23, 61.17, 51.69, 44.33. MS (ESI, m/z) 482.0 [M+H]⁺. Anal. calcd. for C₂₆H₂₃N₇O₂ × 2 HCl × 2.2 H₂O (Mr = 594.14): C 52.56, H 4.99, N 16.50; found: C 52.64, H 5.12, N 16.29%.

Spectroscopic experiments

Polynucleotides

Polynucleotides were purchased as follows: polyG–polyC, polyA–polyU (Sigma-Aldrich, St. Louis, MO), calf thymus ctDNA (Aldrich). Polynucleotides were dissolved in PBS buffer, $I=0.05$ mol dm⁻³, pH 7.0. The calf thymus ctDNA was additionally sonicated and filtered through a 0.45 mm filter. The polynucleotide concentration was spectroscopically determined as the concentration of nucleobases⁶².

UV-Vis spectroscopy

All UV-Vis absorbance measurements were conducted on a Perkin Elmer Lambda 25 spectrophotometer (Perkin Elmer, Waltham, MA). A quartz cell with a 1 cm path length was used for all absorbance studies. Compound stock solutions were 1 mM. The DNA/RNA at

Table 1. Hypochromic effects (H/%)^a, binding constants (log K_s)^b and ratios n^c ([compound]/[polynucleotide phosphate]) calculated from the UV-Vis titrations of compounds with ds-DNA/RNA (PBS, $I=0.015$ M, and pH = 7).

Compound	ctDNA			polyA-polyU			polyC-polyG		
	H/%) ^c	log K _s	n	H/%) ^c	log K _s	n	H/%) ^c	log K _s	n
7a	7.8	6.76	0.27	19.3	5.24	0.31	5.26	6.44	0.40 ^d
7b	22.1 ^e	–	–	27.9 ^e	–	–	13.7	6.27	0.73
7c	36.3	6.24	0.58	38.9	5.21	0.18	4.82 ^e	–	–
7d	40.4	5.78	0.59	32.5	5.94	0.11	4.96	6.56	0.36
7e	38.2	5.33	0.61	31.7	6.20	0.29	5.79	5.89	0.69
8a	41.0	6.17	0.64	46.5	5.87	0.24	5.86	6.17	0.4 ^d
8b	29.7	6.06	0.62 ^f	57.8	5.27	0.23	5.05	6.39	0.39
8c	33.8	5.64	0.69	50.4	6.00	0.19	5.31	6.43	0.36
8d	41.2	5.93	0.47	53.8	6.13	0.30	6.13	5.54	0.40 ^d
8e	44.2	6.39	0.36 ^f	47.2	5.96	0.30	5.96	7.20	0.28
9a	25.7 ^e	–	–	32.7 ^e	–	–	–	6.21	0.40 ^d
9b	18.9 ^e	–	–	31.6 ^e	5.46	0.30 ^d	5.46 ^e	–	–
9c	11.7	6.43	0.35	29.3	5.38	0.29	5.34	6.43	0.36
9d	24.6	5.84	0.75	55.5 ^e	5.89	0.30 ^d	5.89	6.59	0.41
9e	41.1	6.21	0.12	31.6	5.36	0.26	5.21	4.29	0.4 ^d

^aHypochromic effect calculated by Scatchard equation for compounds; $H = (\text{Abs}(\text{compound}) - \text{Abs}(\text{complex})) / \text{Abs}(\text{compound}) \times 100$.

^bTitration data were processed according to the Scatchard Equation^{63,64}.

^cAccuracy of $n \pm 10$ –30%, consequently logK_s values vary in the same order of magnitude.

^d $n = \text{fix}$.

^eHypochromic effect calculated from experimental data.

^fMixed binding mode and binding constants were calculated in range $r \geq 0.1$.

–: changes were too small for accurate calculation of binding constants.


increasing ratios was then titrated into the compound buffer solution (1.48×10^{-5} mol dm⁻³) and the corresponding absorption spectra were recorded under the same conditions. All data were graphed and analysed using Origin software version 9.0 (OriginLab Corporation, Northampton, MA). The stability constants (K_s) and [bound compound]/[polynucleotide phosphate] ratios (n) were calculated according to the Scatchard Equation^{63,64}. Values for K_s and n given in Table 1 all have satisfying correlation coefficients (0.99).

Thermal melting (T_m)

T_m experiments were conducted with a Perkin Elmer Lambda 25 spectrophotometer in 1 cm quartz cuvettes. The absorbance of the DNA/RNA-compound complex was monitored at 260 nm as a function of temperature. The absorbance of the ligands was subtracted from every curve, and the absorbance scale was normalised. The ΔT_m values were calculated by subtracting T_m of the free nucleic acid from T_m of the complex. Every reported ΔT_m value was the average of at least two measurements. The error of ΔT_m is ± 0.5 °C. All data were graphed and analysed using Origin software version 9.0.

Circular dichroism (CD)

The CD spectra of DNA/RNA (concentration in cuvette 2×10^{-5} M) were recorded with a JASCO J-800 spectrometer (JASCO UK Ltd., Dunmow, United Kingdom) at different ratios $r = 0.1, 0.3, 0.5$, and 0.7 ($r = [\text{compound}] / [\text{polynucleotide}]$) at 25 °C in aqueous buffer solution (pH = 7, PBS, and $I = 0.05$ mol dm⁻³). Titrations were carried out by addition of aliquots of 1 mM stock solutions of the relevant compound (at increasing ratios) to the buffered polynucleotide (DNA/RNA) solution in a 1 cm quartz cuvette and scanned over a wavelength range 220–450 nm. All data were graphed and analysed using Origin software version 9.0.



Scheme 1. Synthesis of 2,5-disubstituted benzimidazoles. (i): propargyl bromide, K_2CO_3 , EtOH, reflux; (ii): corresponding azides, $CuSO_4$, $Cu(0)$, DMF, t-BuOH: $H_2O = 1: 1$, $80^\circ C$; (iii): *o*-phenylenediamine (4–6), $NaHSO_3$, EtOH, reflux; HCl/MeOH, room temperature.

Biological evaluations

Anti-bacterial screening

The compounds were evaluated for their *in vitro* anti-bacterial activity against Gram-positive bacteria: *S. aureus* (ATCC 25923), MRSA, methicillin-sensitive *S. aureus* (MSSA), *E. faecalis*, vancomycin-resistant *E. faecium* (VREF), and Gram-negative bacteria: *E. coli* (ATCC 25925), *P. aeruginosa* (ATCC 27853), *A. baumannii* (ATCC 19606) and ESBL-producing *K. pneumoniae* (ATCC 27736). Standard broth microdilution method as recommended in guidelines of Clinical and Laboratory Standards Institute^{61,65,66} was applied and the minimum inhibitory concentration (MIC) of compounds was tested. In short, testing was performed in U-bottomed 96-well sterile plastic microdilution trays (Falcon 3077, Becton Dickinson Labware, Franklin Lakes, NJ) in cation (Ca^{2+} and Mg^{2+}) adjusted Mueller–Hinton broth medium (Becton Dickinson and Co., Cockeysville, MD). All testings were performed in triplicate.

Anti-trypansomal screening and cytotoxicity assays

Bloodstream form *T. brucei* (strain 221) were cultured in modified Iscove's medium, as outlined⁶⁷ and trypanocidal assays were performed using 96-well microtitre plates. The compound concentrations that inhibited growth by 50% (IC_{50}) and 90% (IC_{90}) were determined. Parasites were sub-cultured at $2.5 \times 10^4 ml^{-1}$, compounds were added at range of concentrations, and the plates incubated at $37^\circ C$. Resazurin was added after 48 h, the plates incubated for a further 16 h, and then read in a Spectramax plate reader (Molecular Devices Corporation, San Jose, CA). The data were analysed using GraphPad Prism (GraphPad, La Jolla, CA). Each drug concentration was tested in triplicate.

Cytotoxicity against mammalian cells was also assessed using microtitre plates. Briefly, L6 cells (a rat myoblast line) were seeded at $1 \times 10^4 ml^{-1}$ in 200 μl of growth medium containing different compound concentrations. The plates were then incubated for 6 d at $37^\circ C$ and 20 μl resazurin added to each well. After a further 8 h incubation, the fluorescence was determined using a Spectramax plate reader, as outlined above.

Results and discussion

Chemistry

1,2,3-Triazole-linked 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** are synthesised as outlined in Scheme 1. 4-Hydroxybenzaldehyde was propargylated to give 4-(prop-2-ynoxy)benzaldehyde (**2**), which subsequently *via* the regioselective Cu(I) catalysed cycloaddition with aromatic azides resulted in 4-(1,2,3-triazol-1-yl)benzaldehyde derivatives (**3a–3e**) comprising an *N*-1-aryl-substituted 1,2,3-triazole subunit. An efficient and environmentally benign synthetic protocol⁶⁸, applying microwave and ultrasound irradiation, was used in the synthesis of **3a–3e**. The efficiency of both ultrasound and microwave conditions were compared and indicated that ultrasound-assisted syntheses of **3a–3e** resulted in higher yields than those of microwave-assisted reactions. Amidino-substituted 1,2-phenylenediamines (**4–6**) that were used for the synthesis of the target 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** were synthesised from the corresponding nitrile by the Pinner method⁵⁸. 4-Amidino 1,2-phenylenediamines (**4–6**) reacted with the bisulfite adduct of the 4-(1,2,3-triazol-1-yl)benzaldehyde derivatives (**3a–e**) to produce amidine (**7a–7e**), *N*-isopropylamidine (**8a–8e**), and imidazoline-substituted (**9a–9e**) benzimidazole derivatives⁶⁹.

Spectroscopic characterisation of compounds

5-Amidinobenzimidazole derivatives **7a–7e**, **8a–8e**, and **9a–9e** were synthesised and characterised by UV–Vis spectroscopy. UV–Vis spectra displayed two absorption maxima at around 260 and 315 nm (Table S1, Supporting Information). Absorbancies of solutions were proportional to their concentrations up to $1 \times 10^{-4} \text{ mol dm}^{-3}$, indicating that there is no significant intermolecular stacking that could give rise to hypochromic effects. Furthermore, the UV–Vis spectra of **7a–7e**, **8a–8e**, and **9a–9e** revealed negligible temperature dependent changes ($25\text{--}90^\circ C$) and excellent reproducibility upon cooling to $25^\circ C$. The results showed that all evaluated compounds were stable and suitable for further spectroscopic and biological investigations.

Interactions with double-stranded polynucleotides

Spectrophotometric titrations of compounds with ds-DNA/RNA

UV-Vis absorption spectroscopy is simple, widely used and one of the most effective methods for detecting the interaction of small molecules with DNA. In general, these interactions and the subsequent formation of a new complex leads to changes in UV-Vis spectra⁷⁰. Therefore, UV-Vis spectroscopy was applied to investigate the interaction of compounds **7a–7e**, **8a–8e**, and **9a–9e** with ds-DNA/RNA. UV-Vis titration with ctDNA showed a hypochromic effect indicating the disappearance of free molecule and the formation of a new compound-DNA species (Figure S1, Supporting Information). The hypochromic effect (12–44%) was accompanied by a small bathochromic shift ($\Delta\lambda = 3–9$ nm) that was found to originate from the stabilisation of DNA secondary structure due to the interaction with small molecules⁷¹.

To assess the sequence selectivity of the compounds, the experiment was repeated with ds-RNA polynucleotides (polyA-polyU and polyC-polyG). The addition of polyA-polyU in most cases led to hypochromic (19–58%) and small bathochromic (2–11 nm) changes in the visible absorption spectra as a result of complex formation. Absorption spectra obtained by adding aliquots of polyC-polyG to the compound solutions were recorded until saturation was achieved. In general, it was observed that addition of polyC-polyG resulted in a pronounced decrease of UV-Vis absorption maxima at 300–320 nm (27–50%), followed by small bathochromic shifts ($\Delta\lambda = 2–7$ nm). No further studies were conducted with compounds whose UV-Vis spectra showed minimal changes ($\Delta A < 0.08$ at $r = 1–0.1$) during titration with DNA/RNA polynucleotides. It can be inferred that these compounds interact with polynucleotides only through a very weak electrostatic and external mode (Table 1). During titration with polyA-polyU, a clear isosbestic point was observed in UV-Vis spectra of **7a** and **9c**, pointing to the formation of one dominant type of complex.

The binding constants $\log K_s$ and the density of the binding sites n were calculated using Scatchard plot analysis. In addition, the binding constants K_s for compounds **8b** and **8e** were calculated only for titration data taken at the $r \geq 0.1$, because below that ratio changes in absorption maxima were too small for accurate calculation ($\Delta A \leq 0.04$) (Table 1). The binding constants K_s and ratios n obtained by processing UV-Vis titration data using the Scatchard equation are summarised in Table 1.

Thermal denaturation experiments

Thermal melting enables the rapid qualitative evaluation of the relative binding affinities of the compounds towards selected polynucleotides (Table 2)^{72,73}. The melting temperature (T_m) is defined as the differences between the melting temperatures of free polynucleotides and their complexes with small non-covalently bound molecules. The correlation between binding constant and the increase of T_m was found to be quite complex, because the number of binding sites, positive charge of compounds, potential cooperativity, and the affinity for the unfolded polynucleotide have also to be taken into account⁷⁴.

Denaturation experiments were carried out at different amounts of the compounds ($r = 0.1, 0.3, 0.5,$ and 0.7 eq; $r = [\text{compound}]/[\text{polynucleotide}]$) with ctDNA and polyA-polyU. The results of the denaturation experiments are listed in Table 2.

Generally, results correlated with those of UV-Vis experiments. Strong non-linear dependence of ΔT_m values on the ratio r was revealed, suggesting saturation of binding sites at $r = 0.5–0.7$ (for **7c–7d**, **8a–8e**, and **9d**), $r = 0.3–0.5$ (for **7a**, **9c**, and **9e**), in good accordance with the calculated values presented in Table 1.

Table 2. ΔT_m values ($^{\circ}\text{C}$) of studied ds-polynucleotides upon addition of compounds **7a**, **7c–7e**, **8a–8e**, and **9b–9e** at different ratio r^b (PBS and $\text{pH} = 7$)^a.

Compound	ctDNA			polyA-polyU		
	0.3	0.5	0.7	0.1	0.3	0.5
7a	2.46	4.84	4.69	1.74	1.74	2.53
7c	2.35	3.20	3.77	0.20	2.72	– ^d
7d	3.12	3.86	3.62	2.06	1.14	1.70
7e	2.19	2.62	2.66	0.39	1.11	1.11
8a	3.35	3.94	4.25	0.32	0.64	1.11
8b	4.03	3.96	4.47	1.17	1.32	1.56
8c	3.40	3.89	4.39	0.76	0.58	1.12
8d	1.76	3.32	3.63	0.91	0.51	0.72
8e	2.22	1.72	1.71	0.52	0.23	0.26
9b	–	–	–	2.49	2.67	2.92
9c	3.55	3.31	3.80	2.85	36.08 ^c	40.93 ^c
9d	3.31	3.52	2.60	1.26	4.27	5.53
9e	2.87	3.47	3.60	1.11	13.99 ^c	17.73 ^c
					10.30 ^c	13.29 ^c
					0.47	0.47
					12.46 ^c	13.89 ^c

^aAll values are averaged from at least two measurements. Error in ΔT_m : $\pm 0.5^{\circ}\text{C}$.

^b $r = [\text{compound}]/[\text{polynucleotide}]$.

^cBiphasic melting curve, values for both melting midpoints given when possible.

^dNot possible to determine due to the lack of melting midpoint.

Results showed that compounds **8a–8e** stabilised ctDNA slightly better than compounds **7a–7e** and **9a–9e**. Biphasic curves for interactions of compounds **7e**, **8b**, and **9b–9e** with polyA-polyU at higher ratios r indicated additional binding modes. The above-mentioned compounds have monophasic curves at $r \leq 0.3$, which together with results on UV-Vis titration confirmed intercalation as the dominant binding mode, while above that, ratio biphasic curves indicated agglomeration of compounds along the polynucleotide chains.

Circular dichroism (CD) experiments

CD spectroscopy has been extensively employed for the investigation of small molecule-polynucleotide (DNA/RNA) interactions^{75,76}. Binding of achiral small molecules within the chiral DNA/RNA helix results in an induced CD spectrum (ICD)^{77,78}. The appearance of ICD bands upon titration ($r = 0.1–0.7$) at $\lambda > 300$ nm was used to estimate the orientation of the chromophore in the ctDNA/RNA binding site and for the determination of binding mode. ctDNA features approximately 40% GC and 60% AT base pairs and adopts a B-helix with a narrow, deep, well-accessible minor groove and a rather broad, and shallow major groove. The two RNA polymers, polyA-polyU and polyG-polyC, form a typical A-helix with a broad minor and narrow major groove. The main difference among ds-RNAs is the presence of the amino group at N-2 in guanine which protrudes into the grooves and thereby may influence the affinity and binding mode of compounds being studied. The addition of the compounds being investigated resulted in a decrease of the ds-DNA/RNA CD bands ($\lambda = 220–400$ nm, S2). Observed changes in the intensity of CD bands for ds-DNA/RNA indicated the partial disruption of the polynucleotide helical chirality upon binding of a small molecule. The addition of the compounds **7a**, **7c–7e**, **8a–8e**, and **9c–9d** in solution with ctDNA generated strong, positive ICD signals in the range of 300–350 nm (Figures 4 and S2, Supporting Information). This may arise due to groove binding being the dominant binding mode for this class of compounds^{79,80}.

ICD spectra of polyA-polyU and polyC-polyG with the addition of evaluated compounds, except for **7a**, **8a–8e**, and **9d**, showed a




Figure 4. Induced CD spectra of compound **7a** (a) and compound **8c** (b) with *ctDNA* ($r=0-0.7$).




Figure 5. ICD spectra of RNA polynucleotides with 5-amidinobenzimidazoles with *p*-methoxyphenyl-1,2,3-triazole unit: compound **7b** (a), compound **8b** (b), and compound **9b** (c).

Table 3. Anti-bacterial activity of selected compounds against antibiotic-resistant Gram-positive clinical strains.

Compound	MIC ($\mu\text{g/ml}$)		
	<i>S. aureus</i> MRSA	<i>S. aureus</i> MSSA	<i>E. faecium</i> VRE
7a	16	32	32
7b	–	–	256
7c	16	32	256
7d	16	32	32
7e	32	128	64
8a	8	128	128
8b	16	64	128
8c	8	16	32
8d	32	64	64
8e	8	64	64
9a	128	128	128
9b	256	256	256
9c	8	128	64
9d	64	64	64
9e	64	64	32
Ampicillin	4	1	1
Gentamicin	0.25	0.125	0.25

decrease of CD band in the range of 220–300 nm, followed by appearance of new negative signal at >300 nm (Figures 5 and S2, Supporting Information). This indicates that intercalation is the dominant binding mode. Compounds **7b–9b** showed higher affinity for dsRNA than *ctDNA*. While **8b** and **9b** bound to polyA-polyU, **7b** showed higher affinity for polyC-polyG (Figures 5 and S2, Supporting Information).

ICD spectra of **8b** and **9b**, in the presence of polyA-polyU, showed an intense increase of signal above $r=0.3$, while ICD spectra of **7b** with polyC-polyG showed a weaker intercalation signal above $r=0.5$. This is in agreement with the results obtained

Table 4. Anti-bacterial activity of selected compounds against antibiotic-resistant Gram-negative clinical strains.


Compound	MIC ($\mu\text{g/ml}$)		
	<i>E. coli</i> ESBL	<i>K. pneumoniae</i> ESBL	<i>P. aeruginosa</i> ESBL
7a	4	8	128
7d	16	16	32
7e	32	16	32
9d	128	–	128
9e	64	–	64
Ceftazidime	8	>128	32
Ciprofloxacin	>128	1	8

by UV-Vis and thermal melting methods. Minimal changes of the intensity of the CD bands of polyC-polyG upon titration with compounds **7a**, **8a–8e**, and **9d**, suggest a non-specific binding mode. Most probably compounds bind on the outside of the polyC-polyG polynucleotide. The intensity of negative ICD bands in polyA-polyU ICD spectra was also observed to be more intense than those in polyC-polyG spectra obtained with the same compound.

Biological evaluations

In vitro anti-bacterial activity

The *in vitro* anti-bacterial activity of 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** was tested against Gram-positive bacteria including *S. aureus* (ATCC 25923), *Enterococcus faecalis* (ATCC 29212), and Gram-negative bacteria including *E. coli* (ATCC 25925), *K. pneumoniae* (ATCC 700803), *P. aeruginosa* (ATCC 27853), and *Acinetobacter baumannii* (ATCC 19606). The MICs were determined

Table 5. Anti-trypanosomal activity^a of compounds **7a–7e**, **8a–8e**, and **9a–9e** against *Trypanosoma brucei* strain.


Compd	R ₁	R ₂	<i>T. brucei</i>		L6 cells	S.I. ^c
			IC ₅₀ (μM)	IC ₉₀ (μM)	IC ₅₀ (μM)	L6/Tb IC ₅₀
7a			8.6 ± 0.5	16.2 ± 0.9	-	-
7b			1.5 ± 0.3	8.1 ± 0.6	302 ± 15	200
7c			>15	-	-	-
7d			12.9 ± 0.2	18.2 ± 1.0	-	-
7e			10.2 ± 1.3	15.9 ± 0.4	-	-
8a			7.1 ± 0.7	16.7 ± 1.2	-	-
8b			1.1 ± 0.3	3.5 ± 0.2	>300	>270
8c			>15	-	-	-
8d			12.9 ± 0.2	21.6 ± 0.4	-	-
8e			13.5 ± 0.8	22.5 ± 0.3	-	-
9a			7.9 ± 0.4	17.2 ± 1.2	-	-
9b			1.6 ± 0.4	7.3 ± 0.3	263 ± 15	165
9c			>15	-	-	-
9d			10.8 ± 0.4	>25	-	-
9e			9.7 ± 0.2	14.0 ± 0.3	-	-
Nifurtimox	-	-	4.4 ± 0.7 ^b	-	-	-

^a*In vitro* activity against bloodstream form *T. brucei* expressed as the concentration that inhibited growth by 50% (IC₅₀) and 90% (IC₉₀). Data are the mean of triplicate experiments ± SEM.

^bTaken from Ref. [83].

^cSelectivity index.

and compared with those of the antibiotics ceftazidime, ciprofloxacin, ampicillin, and gentamicin (Table S2, Supporting Information).

Generally, compounds showed better activities against Gram-positive than Gram-negative bacteria. Only 5-amidinobenzimidazoles **7a**, **7d**, and **7e** proved to be active against three Gram-negative strains, particularly amidinobenzimidazole **7d**, which has an *N*-1-benzyl substituent. The type of amidino moiety in 5-benzimidazole had impact on the anti-bacterial activities, with non-substituted amidinobenzimidazoles **7a–7e** having the highest overall activities (Table S2, Supporting Information). Compounds that exhibited anti-bacterial activities with MIC <256 μg/ml were evaluated against antibiotic resistant Gram-positive clinical strains, such as MRSA, MSSA and VREF (Table 3) and Gram-negative clinical strains including extended-spectrum β-lactamase (ESBL)-producing *E. coli*, *K. pneumoniae*, and *P. aeruginosa* (Table 4).

The evaluated compounds had a wide range of activity against MRSA, with the 5-*N*-isopropylamidinobenzimidazoles **8a–8e** being the most active (MIC = 8–32 μg/mL) (Table 3). **8a–8e** were also

active against the MSSA strain, although to a lesser extent (MIC = 16–128 μg/ml). **8c** also displayed modest activity against VRE-*E. faecium*. Among other compounds, benzimidazole imidazoline **9c** had promising activity against the MRSA strain (MIC = 8 μg/ml). Against the antibiotic-resistant Gram-negative bacteria (Table 4), 5-amidinobenzimidazole **7a**, with the *N*-1-phenyl-1,2,3-triazole, proved to be the most potent, with IC₅₀ values of 4 μg/ml for *E. coli*, and 8 μg/ml for *K. pneumoniae*. However, this compound was only marginally effective against *P. aeruginosa*. Compounds **7d** and **7e** prove to be active against *K. pneumoniae* (MIC = 16 μg/ml). Introduction of a methylene (**7d** and **9d**) and sulphide-bridge (**7e** and **9e**) between 1,2,3-triazole and the phenyl ring reduced the activity against the antibiotic resistant *E. coli* and *K. pneumoniae* clinical strains. **7d**, **7e**, and **9e** had slightly greater potency against *P. aeruginosa* compared with **7a**. Overall, the results indicated that the *o*-chlorophenyl hydrophobic unit, with *N*-isopropylamidine, as the hydrophilic unit, in **8c** contributed to anti-bacterial activity, particularly against the MRSA strain. Importantly, **7a** was the most

potent of the compounds against ESBL-producing *E. coli*, with higher activity than the reference antibiotics ceftazidime and ciprofloxacin.

One of our aims was to determine if there was a relationship between the affinity of compounds towards ds-DNA/RNA and their antimicrobial activity. UV-Vis and CD spectroscopy, as well as thermal denaturation assays, showed that compounds **7b**, **9a**, and **9b**, which did not bind to ctDNA, had only marginal anti-microbial activities (MIC \geq 128 μ g/ml). Conversely, 5-amidinobenzimidazole **7a**, which showed the highest affinity to ctDNA, exhibited high potency against ESBL-producing *E. coli*, which is in agreement with previous findings^{56,81,82}.

Screening of the anti-trypanosomal activity

Results on the *in vitro* testing against the bloodstream form *T. brucei* of the 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** with 1,4-disubstituted 1,2,3-triazole, and nifurtimox as reference drug, are summarised in Table 5. Similarly to anti-bacterial evaluations, we investigated how cationic moieties and aromatic substituents attached to the N-1 of the 1,2,3-triazole ring directly, or through the methylene and methylenesulphide spacer, influenced, anti-trypanosomal potencies.

Phenyl, *p*-methoxyphenyl, *o*-chlorophenyl, benzyl and (phenylthio)methyl substituents had a significant negative impact on IC₅₀ values of anti-trypanosomal activity in the following order: *p*-OCH₃ > Ph > PhSCH₂ \approx Bn > *o*-Cl. Except for **7c–9c**, all compounds were active against *T. brucei* with IC₅₀ values ranging from 1.1 to 13.5 μ M. Interestingly, the *o*-chlorophenyl substituent in **7c–9c** caused the loss of anti-trypanosomal activity (IC₅₀ > 15 μ M). The presence of the *p*-methoxyphenyl substituent in **7b–9b** led to enhanced anti-trypanosomal potency, with the 5-*N*-isopropylamidinobenzimidazole analogue **8b** being the most promising compound (IC₅₀ = 1.1 μ M, IC₉₀ = 3.5 μ M), which is 4-fold more potent than nifurtimox. UV-Vis titrations and thermal denaturation assays suggested that **7b–9b** have low affinity to ctDNA (Table 1) indicating that DNA is not the primary target for their anti-trypanosomal activity. Cytotoxicity assays against the rat myoblast cell line L6, revealed negligible activity, with three-figure selectivity index (Table 5).

Conclusions

The 1,2,3-triazole-linked 5-amidinobenzimidazoles **7a–7e**, **8a–8e**, and **9a–9e** were synthesised by a Cu(I)-catalysed 1,3-dipolar cycloaddition reaction applying microwave and ultrasound irradiation, with subsequent formation of a benzimidazole moiety by oxidative coupling of *o*-phenylenediamines with benzaldehydes. It was found that the **7c–9c**, **7d–9d**, and **7e–9e** sets of compounds non-covalently bound to ds-DNA/RNA. The small bathochromic shifts in UV-Vis titration spectra upon addition of ctDNA, modest thermal stabilisation effects, and strong positive ICD bands in CD titration experiments supported minor groove binding as the dominant binding mode of these compounds. Conversely, the appearance of negative ICD bands in CD titration experiments with polyA-polyU and polyC-polyG, and density of binding sites obtained from UV-Vis titrations, identified intercalation as the predominant binding mode.

Furthermore, SARs showed that the type of aromatic substituents at N-1 of 1,2,3-triazole had profound effects on anti-bacterial and anti-protozoal activities. Thus, results of anti-bacterial evaluations revealed that *o*-chlorophenyl-1,2,3-triazole and *N*-isopropylamidine moieties in **8c** had a considerable impact on inhibitory

activity against resistant Gram-positive bacteria, particularly the MRSA strain. On the other hand, non-substituted amidine and phenyl rings in **7a** contributed to a strong inhibitory effect on an ESBL-producing *E. coli* strain, with the potency better than those of the reference antibiotics ceftazidime and ciprofloxacin. Compounds **7b**, **9a**, and **9b** that showed extremely low affinity to ctDNA had also negligible anti-microbial activity (MIC \geq 128 μ g/ml). Contrary to this, the 5-*N*-isopropylamidinobenzimidazole series **8a–8e**, which had better binding affinity relative to other amidines, showed some selective activity (MIC = 8–32 μ g/ml) against the MRSA strain. Notably, compound **7a** emerged as the most promising candidate because of its higher potency (MIC = 4 μ g/ml) against ESBL-producing *E. coli*. It had the highest affinity among the tested compounds to ctDNA (Tables 1 and 2).

Results of anti-trypanosomal evaluations showed that the *o*-chlorophenyl group in **7c–9c** had a negative impact on activity, whereas the *p*-methoxyphenyl substituent in **7b–9b** enhanced activity, with **8b** (IC₅₀ = 1.1 μ M and IC₉₀ = 3.5 μ M) being more potent than nifurtimox. In contrast to the observed correlation between anti-microbial activity and DNA binding, the antiprotozoal effects of **8b** did not correlate with its DNA affinity. Further investigations will, therefore, be required to clarify the mechanism of anti-protozoal activity.

The promising anti-bacterial activity of compounds **7a** and **8c** and the anti-trypanosomal potency of compound **8b** suggest that further structural optimisation of the 1,2,3-triazole-linked 5-amidinobenzimidazole class could enhance the potential anti-HAT and anti-bacterial activity against resistant pathogenic microorganisms.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

We greatly appreciate the financial support of the Croatian Science Foundation (project No. IP-2013–11-5596) and University of Osijek, Faculty of Medicine [research grant VIF2016-MEFOS-27].

References

1. Akhtar W, Khan MF, Verma G, et al. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. *Eur J Med Chem* 2017;126:705–53.
2. Akhtar J, Khan AA, Ali Z, et al. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. *Eur J Med Chem* 2017;125:143–89.
3. Yadav G, Ganguly S. Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: a mini-review. *Eur J Med Chem* 2015;97:419–43.
4. Akhtar MJ, Siddiqui AA, Khan AA, et al. Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors. *Eur J Med Chem* 2017;126:853–69.
5. Bhattacharya S, Chaudhuri P. Medical implications of benzimidazole derivatives as drugs designed for targeting DNA and DNA associated processes. *Curr Med Chem* 2008;15:1762–77.
6. Sontakke VA, Lawande PP, Kate AN, et al. Antiproliferative activity of bicyclic benzimidazole nucleosides: synthesis, DNA-binding and cell cycle analysis. *Org Biomol Chem* 2016;14:4136–45.

7. Hegde M, Kumar KSS, Thomas E, et al. A novel benzimidazole derivative binds to the DNA minor groove and induces apoptosis in leukemic cells. *RSC Adv* 2015;5:93194–208.
8. Singla P, Luxami V, Paul K. Triazine–benzimidazole conjugates: synthesis, spectroscopic and molecular modelling studies for interaction with calf thymus DNA. *RSC Adv* 2016;6:14741–50.
9. Chaudhuri P, Ganguly B, Bhattacharya S. An experimental and computational analysis on the differential role of the positional isomers of symmetric bis-2-(pyridyl)-1H-benzimidazoles as DNA binding agents. *J Org Chem* 2007;72:1912–23.
10. Thomas JR, Hergenrother PJ. Targeting RNA with small molecules. *Chem Rev* 2008;108:1171–224.
11. Guan L, Disney MD. Recent advances in developing small molecules targeting RNA. *ACS Chem Biol* 2012;7:73–86.
12. Zheng Y, Cai X, Bradley JE. MicroRNAs in parasites and parasite infection. *RNA Biol* 2013;10:371–9.
13. Cheng G, Dai M, Ahmed S, et al. Antimicrobial drugs in fighting against antimicrobial resistance. *Front Microbiol* 2016;7:470.
14. Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. *Front Microbiol* 2014;5:551.
15. Yang SW, Pan J, Yang C, et al. Benzimidazole analogs as WTA biosynthesis inhibitors targeting methicillin resistant *Staphylococcus aureus*. *Bioorg Med Chem Lett* 2016;26:4743–7.
16. Hu L, Kully ML, Boykin DW, Abood N. Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents. *Bioorg Med Chem Lett* 2009;19:3374–7.
17. Rodrigo-Troyano A, Sibila O. The respiratory threat posed by multidrug resistant Gram-negative bacteria. *Respirology* 2017;22:1288–99.
18. Ansari KF, Lal C. Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents. *Eur J Med Chem* 2009;44:2294–9.
19. Sharma D, Narasimhan B, Kumar P, Jalbout A. Synthesis and QSAR evaluation of 2-(substituted phenyl)-1H-benzimidazoles and [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones. *Eur J Med Chem* 2009;44:1119–27.
20. Ates-Alagoz Z. Antimicrobial activities of 1-H-benzimidazole-based molecules. *Curr Top Med Chem* 2016;16:2953–62.
21. Song D, Ma S. Recent development of benzimidazole-containing antibacterial agents. *Chem Med Chem* 2016;11:646–59.
22. Desai N, Trivedi A, Pandit U, et al. Hybrid bioactive heterocycles as potential antimicrobial agents: a review. *Mini Rev Med Chem* 2016;16:1500–26.
23. El-Gohary NS, Shaaban MI. Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, quorum-sensing and antitumor agents. *Eur J Med Chem* 2017;131:255–62.
24. Klimesová V, Kocí J, Pour M, et al. Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents. *Eur J Med Chem* 2002;37:409–18.
25. Gibney KA, Sovadinova I, Lopez AI, et al. Poly(ethylene imine)s as antimicrobial agents with selective activity. *Macromol Biosci* 2012;12:1279–89.
26. Sharma V, Chitranshi N, Agarwal AK. Significance and biological importance of pyrimidine in the microbial world. *Int J Med Chem* 2014;2014:202784.
27. Anthony NG, Breen D, Clarke J, et al. Antimicrobial lexitropins containing amide, amidine, and alkene linking groups. *J Med Chem* 2007;50:6116–25.
28. Bonandi E, Christodoulou MS, Fumagalli G, et al. The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. *Drug Discov Today* 2017;22:1572–81.
29. Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: current developments. *Bioorg Chem* 2017;71:30–54.
30. Tiwari VK, Mishra BB, Mishra KB, et al. Cu-catalyzed click reaction in carbohydrate chemistry. *Chem Rev* 2016;116:3086–240.
31. DeSimone RW, Currie KS, Mitchell SA, et al. Privileged structures: applications in drug discovery. *Comb Chem High Throughput Screening* 2004;7:473–93.
32. Gaba M, Singh S, Mohan C. Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents. *Eur J Med Chem* 2014;76:494–505.
33. Jadhav GR, Shaikh MU, Kale RP, et al. SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazoles as antimicrobial and antituberculosis agents. *Eur J Med Chem* 2009;44:2930–5.
34. Kühler TC, Swanson M, Christenson B, et al. Novel structures derived from 2-[[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-*Helicobacter pylori* agents, Part 1. *J Med Chem* 2002;45:4282–99.
35. Marčić S, Kraljević TG, Paljetak HČ, et al. 1,2,3-Triazole pharmacophore-based benzofused nitrogen/sulfur heterocycles with potential anti-*Moraxella catarrhalis* activity. *Bioorg Med Chem* 2015;23:7448–63.
36. Ranjan N, Story S, Fulcrand G, et al. Selective inhibition of *Escherichia coli* RNA and DNA topoisomerase I by Hoechst 33258 derived mono- and bisbenzimidazoles. *J Med Chem* 2017;60:4904–22.
37. Grillot AL, Tiran AL, Shannon D, et al. Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability. *J Med Chem* 2014;57:8792–816.
38. Janupally R, Jeankumar VU, Bobesh KA, et al. Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyrase B enzyme of *Staphylococcus aureus*. *Bioorg Med Chem* 2014;22:5970–87.
39. Lam T, Hilgers MT, Cunningham ML, et al. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines. *J Med Chem* 2014;57:651–68.
40. Whalen KL, Chau AC, Spies MA. In silico Optimization of a Fragment-Based Hit Yields Biologically Active, High-Efficiency Inhibitors for Glutamate Racemase. *ChemMedChem* 2013;8:1681–1689.
41. Pan W, Fan M, Wu H, et al. A new small molecule inhibits *Streptococcus mutans* biofilms in vitro and in vivo. *J Appl Microbiol* 2015;119:1403–11.
42. Luo G, Spellberg B, Gebremariam T, et al. Combination therapy with iron chelation and vancomycin in treating murine staphylococemia. *Eur J Clin Microbiol Infect Dis* 2014;33:845–51.
43. Nimesh H, Sur S, Sinha D, et al. Synthesis and biological evaluation of novel bisbenzimidazoles as *Escherichia coli* topoisomerase IA inhibitors and potential antibacterial agents. *J Med Chem* 2014;57:5238–57.
44. Mann J, Taylor PW, Dorgan CR, et al. The discovery of a novel antibiotic for the treatment of *Clostridium difficile* infections: a story of an effective academic–industrial partnership. *MedChemComm* 2015;6:1420–6.
45. Farahat AA, Bennett-Vaughn C, Mineva EM, et al. Synthesis, DNA binding and antitrypanosomal activity of benzimidazole analogues of DAPI. *Bioorg Med Chem Lett* 2016;26:5907–10.

46. Karaaslan C, Kaiser M, Brun R, Göker H. Synthesis and potent antiprotozoal activity of mono/di amidino 2-anilinobenzimidazoles versus *Plasmodium falciparum* and *Trypanosoma brucei rhodesiense*. *Bioorg Med Chem* 2016;24:4038–44.
47. Ismail MA, Batista-Parra A, Miao Y, et al. Dicationic near-linear biphenyl benzimidazole derivatives as DNA-targeted antiprotozoal agents. *Bioorg Med Chem* 2005;13:6718–26.
48. Rice CA, Colon BL, Alp M, et al. Bis-benzimidazole hits against *Naegleria fowleri* discovered with new high-throughput screens. *Antimicrob Agents Chemother* 2015;59:2037–44.
49. Alp M, Göker H, Brun R, Yildiz S. Synthesis and antiparasitic and antifungal evaluation of 2'-arylsubstituted-1H,1'H-[2,5']bisbenzimidazolyl-5-carboxamidines. *Eur J Med Chem* 2009;44:2002–8.
50. Sola I, Artigas A, Taylor MC, et al. Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents. *Bioorg Med Chem* 2016;24:5162–71.
51. Pai S, Alam AS, Kapoor JN. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia, US. Patent Application US/07383, 243. US5084480 A, Fujisawa USA Inc., 1992.
52. Jensch H4. 4'-Diamidino-diazoaminobenzene, a new agent in the treatment of trypanosomiasis and babesiasis. *Arzneimitt Forsch* 1955;5:634–635.
53. Ansede JH, Anbazhagan M, Brun R, et al. As indicators of in vivo efficacy in a mouse model of *Trypanosoma brucei rhodesiense* infection. *J Med Chem* 2004;47:4335–8.
54. Bakunov SA, Bakunova SM, Wenzler T, et al. Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles. *J Med Chem* 2010;53:254–72.
55. Bistrovic A, Krstulovic L, Harej A, et al. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. *Eur J Med Chem* 2018;143:1616–34. 2017
56. Stolic I, Paljetak HC, Peric M, et al. Synthesis and structure–activity relationship of amidine derivatives of 3,4-ethylenedioxythiophene as novel antibacterial agents. *Eur J Med Chem* 2015;90:68–81.
57. Krstulovic L, Stolic I, Jukić M, et al. New quinoline-arylamine hybrids: synthesis, DNA/RNA binding and antitumor activity. *Eur J Med Chem* 2017;137:196–210.
58. Hranjec M, Starčević K, Zamola B, et al. New amidino-benzimidazolyl derivatives of tylosin and desmycosin. *J Antibiot* 2002;55:308–14.
59. Chandrika NT, Shrestha SK, Ngo HX, Garneau-Tsodikova S. Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. *Bioorg Med Chem* 2016;24:3680–6.
60. Kumar R, Arora J, Prasad AK, et al. Synthesis and antimicrobial activity of pyrimidine chalcones. *Med Chem Res* 2013;22:5624–32.
61. Harbeck RJ, McCarter YS, Ortez JH, et al. Manual of antimicrobial susceptibility testing, Washington: American Society for Microbiology; 2005.
62. Stolic I, Mišković K, Magdaleno A, et al. Effect of 3,4-ethylenedioxy-extension of thiophene core on the DNA/RNA binding properties and biological activity of bisbenzimidazole amidines. *Bioorg Med Chem* 2009;17:2544–54.
63. Scatchard G. The attractions of proteins for small molecules and ions. *Ann NY Acad Sci* 1949;51:660–72.
64. McGhee JD, von Hippel PH. Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. *J Mol Biol* 1974;86:469–89.
65. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A7, Wayne (PA): CLSI; 2006.
66. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. M100-S17, Wayne (PA): CLSI; 2007.
67. Taylor MC, Lewis MD, Fortes Francisco A, et al. The *Trypanosoma cruzi* vitamin C dependent peroxidase confers protection against oxidative stress but is not a determinant of virulence. *PLoS Negl Trop Dis* 2015;9:e0003707.
68. Kappe CO, Van der Eycken E. Click chemistry under non-classical reaction conditions. *Chem Soc Rev* 2010;39:1280–90.
69. Ohemeng KA, Nguyen VN. Ortho -Mcneil Pharmaceutical. 2-substituted phenylbenzimidazole antibacterial agents, US. Patent Application 08/924,558, 1999, WO1999011627A1.
70. Rehman SU, Sarwar T, Husain MA, et al. Studying non-covalent drug–DNA interactions. *Arch Biochem Biophys* 2015;576:49–60.
71. Arjmand F, Parveen S, Afzal M, et al. Molecular drug design, synthesis and crystal structure determination of Cu II–Sn IV heterobimetallic core: DNA binding and cleavage studies. *Eur J Med Chem* 2012;49:141–50.
72. Banerjee M, Farahat AA, Kumar A, et al. Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides. *Eur J Med Chem* 2012;55:449–54.
73. Wilson WD, Tanious FA, Fernandez-Saiz M, Rigl CT. Evaluation of drug–nucleic acid interactions by thermal melting curves. *Methods Mol Biol* 1997;90:219–40.
74. Mergny JL, Lacroix L. Analysis of thermal melting curves. *Oligonucleotides* 2003;13:515–37.
75. Husain MA, Yaseen Z, Rehman SU, et al. Naproxen intercalates with DNA and causes photocleavage through ROS generation. *Febs J* 2013;280:6569–80.
76. Rodger A. Circular dichroism and linear dichroism. *Encyclopedia of Analytical Chemistry*. John Hoboken (NJ): Wiley & Sons, Ltd. 2014.
77. Liu Y, Kumar A, Boykin DW, Wilson WD. Sequence and length dependent thermodynamic differences in heterocyclic diamidine interactions at AT base pairs in the DNA minor groove. *Biophys Chem* 2007;131:1–14.
78. O'Sullivan P, Rozas I. Understanding the guanidine-like cationic moiety for optimal binding into the DNA minor groove. *ChemMedChem* 2014;9:2065–73.
79. Nagle PS, Quinn SJ, Kelly JM, et al. Understanding the DNA binding of novel non-symmetrical guanidinium/2-aminoimidazolium derivatives. *Org Biomol Chem* 2010;8:5558–67.
80. Nguyen B, Tardy C, Bailly C, et al. Influence of compound structure on affinity, sequence selectivity, and mode of binding to DNA for unfused aromatic dicationic related to furamide. *Biopolymers* 2002;63:281–97.
81. Dyatkina NB, Roberts CD, Keicher JD, et al. Minor groove DNA binders as antimicrobial agents. 1. Pyrrole tetraamides are potent antibacterials against vancomycin resistant Enterococci and methicillin resistant *Staphylococcus aureus*. *J Med Chem* 2002;45:805–17.
82. Khalaf AI. Minor groove binders: some recent research in drug development. *Curr Trends Med Chem* 2009;6:53–63.
83. Havrylyuk D, Zimenkovsky B, Karpenko O, et al. Synthesis of pyrazoline–thiazolidinone hybrids with trypanocidal activity. *Eur J Med Chem* 2014;85:245–54.